1. 1117TiPIMvoke010: Randomized phase III study of atezolizumab (atezo) as adjuvant monotherapy after definitive therapy of squamous cell carcinoma of the head and neck (SCCHN). (23rd October 2018) Authors: Haddad, R; Wong, D J; Guo, Y; Fayette, J; Cohen, E E W; Kowgier, M; Sandler, A; Matheny, C; Kabbinavar, F; Raben, D Journal: Annals of oncology Issue: Volume 29(2018)Supplement 8 Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. 49OIMpower133: Patient-reported outcomes (PROs) in a ph1/3 study of first-line (1L) atezolizumab (atezo) + carboplatin + etoposide (CP/ET) in extensive-stage SCLC (ES-SCLC). (17th December 2018) Authors: Califano, R; Każarnowicz, A; Karaseva, N; Sánchez, A; Liu, S V; Horn, L; Quach, C; Yu, W; Kabbinavar, F; Lam, S; Mansfield, A Journal: Annals of oncology Issue: Volume 29(2018)Supplement 10 Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
3. LBA1IMpower133: Primary efficacy and safety + CNS-related adverse events in a phase I/III study of first-line (1L) atezolizumab + carboplatin + etoposide in extensive-stage SCLC (ES-SCLC). (25th November 2018) Authors: Mok, T S K; Reck, M; Horn, L; Lam, S; Shames, D S; Liu, J; Kabbinavar, F; Lin, W; Sandler, A; Liu, S V Journal: Annals of oncology Issue: Volume 29(2018)Supplement 9 Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
4. Safety and clinical activity of atezolizumab in head and neck cancer: results from a phase I trial. (13th September 2018) Authors: Colevas, A D; Bahleda, R; Braiteh, F; Balmanoukian, A; Brana, I; Chau, N G; Sarkar, I; Molinero, L; Grossman, W; Kabbinavar, F; Fassò, M; O'Hear, C; Powderly, J Journal: Annals of oncology Issue: Volume 29:Number 11(2018) Page Start: 2247 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗